^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    cabazitaxel

    i
    Other names: XRP6258, XRP-6258, TXD-258, taxoid-116258, RPR 116258, RPR 116258A, TXD 258
    Company:
    Generic mfg.
    Drug class:
    Microtubule inhibitor
    Related drugs:
    4d
    Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancer (clinicaltrials.gov)
    P3, N=675, Not yet recruiting, Amgen
    New P3 trial • Metastases
    |
    Xtandi (enzalutamide capsule) • abiraterone acetate • cabazitaxel • xaluritamig (AMG 509)
    18d
    CHAMP: A Study of Chemoimmunotherapy for the Treatment of Men With Neuroendocrine or Aggressive Variant Metastatic Prostate Cancer (clinicaltrials.gov)
    P2, N=43, Recruiting, Andrew J. Armstrong, MD | Trial completion date: Jun 2027 --> Jun 2028 | Trial primary completion date: Dec 2024 --> Dec 2025
    Trial completion date • Trial primary completion date
    |
    TP53 (Tumor protein P53) • PTEN (Phosphatase and tensin homolog) • RB1 (RB Transcriptional Corepressor 1) • SYP (Synaptophysin)
    |
    LDH elevation
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • carboplatin • cabazitaxel
    20d
    Testing Whether the Addition of Carboplatin Chemotherapy to Cabazitaxel Chemotherapy Will Improve Outcomes Compared to Cabazitaxel Alone in People With Castrate-Resistant Prostate Cancer That Has Spread Beyond the Prostate to Other Parts of the Body (clinicaltrials.gov)
    P3, N=528, Recruiting, SWOG Cancer Research Network | Not yet recruiting --> Recruiting
    Enrollment open
    |
    carboplatin • cabazitaxel
    21d
    CHAARTED2: Abiraterone Acetate and Antiandrogen Therapy With or Without Cabazitaxel and Prednisone in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer Previously Treated With Docetaxel (clinicaltrials.gov)
    P2, N=223, Active, not recruiting, ECOG-ACRIN Cancer Research Group | Trial primary completion date: Dec 2024 --> Mar 2025
    Trial primary completion date
    |
    AR (Androgen receptor)
    |
    AR splice variant 7 • AR-V7 positive • AR-V7 negative • AR splice variant 7 negative
    |
    docetaxel • abiraterone acetate • prednisone • cabazitaxel
    1m
    CABPOSTAAT: Docetaxel Versus Cabazitaxel Post Abiraterone or Enzalutamide (clinicaltrials.gov)
    P2, N=214, Active, not recruiting, Centre hospitalier de l'Université de Montréal (CHUM) | Trial completion date: Sep 2024 --> Dec 2024 | Trial primary completion date: Jul 2024 --> Dec 2024
    Trial completion date • Trial primary completion date
    |
    docetaxel • Xtandi (enzalutamide capsule) • abiraterone acetate • prednisone • cabazitaxel
    1m
    Construction of anticancer drug incorporated aptamer-functionalized cationic β-lactoglobulin: induction of cell cycle arrest and apoptosis in colorectal cancer. (PubMed, J Biomater Sci Polym Ed)
    A novel nanocarrier, aptamer (AS1411)-conjugated β-lactoglobulin/poly-l-lysine (BLG/Ap/PL) nanoparticles, was developed in this study...By loading cabazitaxel (CTX) onto the nanocarriers, the therapeutic potential of BLG/Ap/PL could be demonstrated...Annexin V/propidium iodide (PI) flow cytometry analysis confirmed that CTX@BLG/Ap/PL induces apoptosis in HCT116 cells. Overall, this study proved that CTX@BLG/Ap/PL had several advantages over free chemotherapeutic drugs and showed promise as a solution to the clinical problems associated with targeted antitumor drug delivery systems.
    Journal
    |
    ANXA5 (Annexin A5)
    |
    cabazitaxel • QN-165
    1m
    Targeted Treatment for Metastatic Prostate Cancer, The PREDICT Trial (clinicaltrials.gov)
    P2, N=474, Not yet recruiting, Alliance for Clinical Trials in Oncology
    New P2 trial
    |
    carboplatin • Xtandi (enzalutamide capsule) • abiraterone acetate • cabazitaxel • Pluvicto (lutetium Lu 177 vipivotide tetraxetan) • Ezharmia (valemetostat)
    1m
    A Study of JNJ-78278343 in Combination With Either JNJ-63723283 (Cetrelimab), Taxane Chemotherapy, or Androgen Receptor Pathway Inhibitors for Metastatic Castration-Resistant Prostate Cancer (clinicaltrials.gov)
    P1, N=200, Recruiting, Janssen Research & Development, LLC | N=345 --> 200
    Enrollment change
    |
    docetaxel • Xtandi (enzalutamide capsule) • abiraterone acetate • prednisone • Nubeqa (darolutamide) • cabazitaxel • Erleada (apalutamide) • cetrelimab (JNJ-63723283) • JNJ-8343
    2ms
    FASN: Fatty Acid Synthase Inhibition in Castration Refractory Prostate Cancer (clinicaltrials.gov)
    P2, N=20, Recruiting, Wake Forest University Health Sciences | Trial completion date: Sep 2024 --> Apr 2026 | Trial primary completion date: Aug 2024 --> Jan 2025
    Trial completion date • Trial primary completion date • Combination therapy
    |
    docetaxel • cabazitaxel • omeprazole
    3ms
    c15-148: Enzalutamide and Cabazitaxel in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer (clinicaltrials.gov)
    P1/2, N=37, Active, not recruiting, OHSU Knight Cancer Institute | Trial completion date: Jul 2024 --> Jan 2025
    Trial completion date • Metastases
    |
    Xtandi (enzalutamide capsule) • cabazitaxel
    3ms
    Fabrication of co-delivery liposomal formulation incorporating carmustine and cabazitaxel displays improved cytotoxic potential and induced apoptosis in ovarian cancer cells. (PubMed, J Biomater Sci Polym Ed)
    In addition, the investigation of fluorescence and protein markers examined the apoptosis mechanistic pathway, and the results indicated that BC-Lipo induced apoptosis due to mitochondrial membrane potential variation. This proof-of-concept study has established the probability of these BCNU-CTX combined treatments as active drug delivery nanocarriers for poorly soluble BCNU and CTX.
    Journal
    |
    ANXA5 (Annexin A5)
    |
    carmustine • cabazitaxel
    3ms
    Advancements in platinum chemotherapy for metastatic castration-resistant prostate cancer: Insights and perspectives. (PubMed, Cancer Treat Rev)
    While taxanes, new hormonal agents, radiopharmaceuticals, and PARP inhibitors offer valuable treatment options, this review explores the potential of platinum chemotherapies (carboplatin, cisplatin, and oxaliplatin) as alternative choices...Further research is underway to evaluate the efficacy of platinum regimens against specific mCRPC histopathological variants, particularly aggressive subtypes where the carboplatin and cabazitaxel combination is already recommended...In conclusion, this review highlights the promising potential of platinum-based chemotherapy as a valuable treatment option for mCRPC. While current evidence is encouraging, ongoing research is essential to further optimize its efficacy, identify optimal combinations with other therapies, and better understand its impact on specific mCRPC subpopulations.
    Review • Journal • BRCA Biomarker • PARP Biomarker • IO biomarker • Metastases
    |
    BRCA (Breast cancer early onset)
    |
    cisplatin • carboplatin • oxaliplatin • cabazitaxel
    4ms
    Phase I/II Study of PEGylated Arginine Deiminase (ADI-PEG20) With Carboplatin and Cabazitaxel in Men With Aggressive Variant Prostate Cancers (AVPC) (clinicaltrials.gov)
    P1/2, N=30, Recruiting, M.D. Anderson Cancer Center | Trial completion date: Sep 2027 --> Dec 2027
    Trial completion date
    |
    TP53 (Tumor protein P53) • PTEN (Phosphatase and tensin homolog) • RB1 (RB Transcriptional Corepressor 1)
    |
    carboplatin • cabazitaxel • Hepacid (pegargiminase)
    4ms
    Overcoming ABCB1 mediated multidrug resistance in castration resistant prostate cancer. (PubMed, Cell Death Dis)
    The few available therapies for mCRPC patients include taxanes docetaxel (DTX) and cabazitaxel (CBZ)...ABCB1-specific inhibitor elacridar reversed CBZ and DTX resistance in RC4-2B cells, confirming ABCB1-mediated resistance mechanism...Finally, inhibition of cyclin-dependent kinases 4/6 (CDK4/6) with small molecule inhibitors (CDK4/6i) potentiated cytotoxic effect of CPT or Ara-C in both parental and resistant cells. Overall, our findings indicate that DNA damaging agents CPT and Ara-C alone or in combination with CDK4/6i can be suggested as a new treatment regimen in CRPC patients, including those that are resistant to taxanes.
    Journal
    |
    ABCB1 (ATP Binding Cassette Subfamily B Member 1) • CDK4 (Cyclin-dependent kinase 4)
    |
    docetaxel • cytarabine • cabazitaxel • elacridar (GF120918)
    4ms
    NCI-2018-01071: Study of Olaparib Maintenance Following Cabazitaxel-Carbo in Men With AVPC (clinicaltrials.gov)
    P2, N=119, Active, not recruiting, M.D. Anderson Cancer Center | Trial completion date: Jun 2024 --> Jun 2025 | Trial primary completion date: Jun 2024 --> Jun 2025
    Trial completion date • Trial primary completion date
    |
    TP53 (Tumor protein P53) • PTEN (Phosphatase and tensin homolog) • RB1 (RB Transcriptional Corepressor 1) • CEACAM5 (CEA Cell Adhesion Molecule 5)
    |
    Lynparza (olaparib) • carboplatin • prednisone • cabazitaxel
    4ms
    Phase I/II Study of PEGylated Arginine Deiminase (ADI-PEG20) With Carboplatin and Cabazitaxel in Men With Aggressive Variant Prostate Cancers (AVPC) (clinicaltrials.gov)
    P1/2, N=30, Recruiting, M.D. Anderson Cancer Center | Trial completion date: Dec 2027 --> Sep 2027 | Trial primary completion date: Dec 2025 --> Sep 2027
    Trial completion date • Trial primary completion date
    |
    TP53 (Tumor protein P53) • PTEN (Phosphatase and tensin homolog) • RB1 (RB Transcriptional Corepressor 1)
    |
    carboplatin • cabazitaxel • Hepacid (pegargiminase)
    4ms
    Opevesostat (MK-5684/ODM-208), an oral CYP11A1 inhibitor, in metastatic castration-resistant prostate cancer (mCRPC): Updated CYPIDES phase II results (ESMO 2024)
    53.0% and 36.8% had previously received both abiraterone and enzalutamide, and 69.7% and 64.7% had received cabazitaxel in patients with and without AR-LBD mutation respectively. Administration of Opevesostat to heavily pre-treated mCRPC patients shows promising antitumor activity. PSA50 responses were most frequent among patients harbouring activating AR-LBD mutations.
    P2 data • Metastases
    |
    AR positive • AR mutation
    |
    Guardant360® CDx
    |
    Xtandi (enzalutamide capsule) • abiraterone acetate • cabazitaxel • opevesostat (MK-5684)
    4ms
    Key genes and molecular mechanisms related to Paclitaxel Resistance. (PubMed, Cancer Cell Int)
    Resistant mechanisms are observed in cancer cells treated with paclitaxel, docetaxel, and cabazitaxel including changes in the target molecule β-tubulin of mitosis, molecular mechanisms that activate efflux drug out of the cells, and alterations in regulatory proteins of apoptosis. Moreover, significant lncRNAs are detected in paclitaxel resistance, such as lncRNA H19 and cross-resistance between taxanes. This review contributed to discovering new treatment strategies for taxane resistance and increasing the responsiveness of cancer cells toward chemotherapeutic drugs.
    Review • Journal
    |
    ABCB1 (ATP Binding Cassette Subfamily B Member 1) • EDIL3 (EGF Like Repeats And Discoidin Domains 3)
    |
    paclitaxel • docetaxel • cabazitaxel
    4ms
    The recovery from taxane mediated apoptosis in PC-3 castration-resistant metastatic prostate cancer cells. (PubMed, Toxicol In Vitro)
    Here, we revealed the reversibility of cabazitaxel (CBZ)-induced apoptosis in PC-3 castration resistant metastatic prostate cancer cells (mCRPC) through the hallmarks of apoptosis...Our study indicates that CBZ treated PC-3 cells can recover after apoptotic cell death. However, advanced molecular analysis should elucidate the relationship between the molecular mechanisms of recovery and taxane response or resistance in PC-3 mCRPC cells.
    Journal • IO biomarker • Metastases
    |
    BCL2 (B-cell CLL/lymphoma 2) • CASP3 (Caspase 3) • ANXA5 (Annexin A5)
    |
    cabazitaxel
    5ms
    CHAARTED2: Abiraterone Acetate and Antiandrogen Therapy With or Without Cabazitaxel and Prednisone in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer Previously Treated With Docetaxel (clinicaltrials.gov)
    P2, N=223, Active, not recruiting, ECOG-ACRIN Cancer Research Group | Trial primary completion date: Jun 2024 --> Dec 2024
    Trial primary completion date • Metastases
    |
    AR (Androgen receptor)
    |
    docetaxel • abiraterone acetate • prednisone • cabazitaxel
    5ms
    Testing Whether the Addition of Carboplatin Chemotherapy to Cabazitaxel Chemotherapy Will Improve Outcomes Compared to Cabazitaxel Alone in People With Castrate-Resistant Prostate Cancer That Has Spread Beyond the Prostate to Other Parts of the Body (clinicaltrials.gov)
    P3, N=528, Not yet recruiting, SWOG Cancer Research Network
    New P3 trial • Metastases
    |
    carboplatin • cabazitaxel
    6ms
    Circulating Biomarkers Predictive of Treatment Response in Patients with Hormone-sensitive or Castration-resistant Metastatic Prostate Cancer: A Systematic Review. (PubMed, Eur Urol Oncol)
    BRCA1/2, ATM, and AR alterations detected in liquid biopsies may help clinicians in management of patients with mPCa. The other circulating biomarkers did not reach the LOE required for routine clinical use and should be validated in prospective independent studies.
    Review • Journal • BRCA Biomarker • PARP Biomarker • IO biomarker • Metastases
    |
    TP53 (Tumor protein P53) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • ATM (ATM serine/threonine kinase)
    |
    docetaxel • abiraterone acetate • cabazitaxel • Xofigo (radium Ra-223 dichloride)
    6ms
    Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A) (clinicaltrials.gov)
    P1/2, N=220, Recruiting, Merck Sharp & Dohme LLC | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Lynparza (olaparib) • docetaxel • cabazitaxel • opevesostat (MK-5684)
    6ms
    A Study of JNJ-78278343 in Combination With Either JNJ-63723283 (Cetrelimab), Taxane Chemotherapy, or Androgen Receptor Pathway Inhibitors for Metastatic Castration-Resistant Prostate Cancer (clinicaltrials.gov)
    P1, N=345, Recruiting, Janssen Research & Development, LLC | Trial completion date: Mar 2026 --> Sep 2027
    Trial completion date
    |
    docetaxel • Xtandi (enzalutamide capsule) • abiraterone acetate • prednisone • Nubeqa (darolutamide) • cabazitaxel • Erleada (apalutamide) • cetrelimab (JNJ-63723283) • JNJ-8343
    6ms
    Exploration of the influence of GOLGA8B on prostate cancer progression and the resistance of castration-resistant prostate cancer to cabazitaxel. (PubMed, Discov Oncol)
    Through CCK-8 assays, we established that GOLGA8B could influence the sensitivity of CRPC cells to cabazitaxel and docetaxel. In conclusion, we identified GOLGA8B as a crucial gene that influences PCa progression and contributes to CRPC resistance to cabazitaxel.
    Journal
    |
    CXCL8 (Chemokine (C-X-C motif) ligand 8) • CLIP4 (CAP-Gly Domain Containing Linker Protein Family Member 4) • CXCL6 (C-X-C Motif Chemokine Ligand 6) • CXCL1 (Chemokine (C-X-C motif) ligand 1) • MAP1B (Microtubule Associated Protein 1B)
    |
    docetaxel • cabazitaxel
    7ms
    A Study of Nivolumab Plus Ipilimumab, Ipilimumab Alone, or Cabazitaxel in Men With Metastatic Castration-Resistant Prostate Cancer (CheckMate 650) (clinicaltrials.gov)
    P2, N=351, Active, not recruiting, Bristol-Myers Squibb | Trial completion date: May 2024 --> Jan 2025
    Trial completion date • Metastases
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • prednisone • cabazitaxel
    7ms
    A Study of JNJ-78278343 in Combination With Either JNJ-63723283 (Cetrelimab), Taxane Chemotherapy, or Androgen Receptor Pathway Inhibitors for Metastatic Castration-Resistant Prostate Cancer (clinicaltrials.gov)
    P1, N=345, Recruiting, Janssen Research & Development, LLC | N=20 --> 345
    Enrollment change • Combination therapy • Metastases
    |
    docetaxel • Xtandi (enzalutamide capsule) • abiraterone acetate • prednisone • Nubeqa (darolutamide) • cabazitaxel • Erleada (apalutamide) • cetrelimab (JNJ-63723283) • JNJ-8343
    7ms
    Cabazitaxel, Carboplatin, and Cetrelimab Followed by Niraparib With or Without Cetrelimab for the Treatment of Aggressive Variant Metastatic Prostate Cancer (clinicaltrials.gov)
    P2, N=120, Active, not recruiting, M.D. Anderson Cancer Center | Recruiting --> Active, not recruiting
    Enrollment closed • Metastases
    |
    PD-L1 (Programmed death ligand 1) • TP53 (Tumor protein P53) • PTEN (Phosphatase and tensin homolog) • RB1 (RB Transcriptional Corepressor 1) • CEACAM5 (CEA Cell Adhesion Molecule 5)
    |
    PTEN mutation
    |
    carboplatin • Zejula (niraparib) • cabazitaxel • cetrelimab (JNJ-63723283)
    7ms
    A Modular Trial of Androgen Signaling Inhibitor Combinations Testing a Risk-Adapted Strategy in Patients with Metastatic Castration-Resistant Prostate Cancer. (PubMed, Clin Cancer Res)
    Adding ipilimumab to AAPA did not improve outcomes in men with androgen responsive mCRPC. Despite the addition of carboplatin+cabazitaxel, men in the Unsatisfactory group had shortened survivals. Adaptive designs can enrich for biologically and clinically relevant disease subgroups, to contribute to the development of marker-informed, risk-adapted therapy strategies in men with prostate cancer.
    Journal • Metastases
    |
    PTEN (Phosphatase and tensin homolog) • RB1 (RB Transcriptional Corepressor 1) • SPP1 (Secreted Phosphoprotein 1) • IGFBP2 (Insulin-like growth factor binding protein 2)
    |
    Yervoy (ipilimumab) • carboplatin • abiraterone acetate • prednisone • cabazitaxel • Erleada (apalutamide)
    7ms
    DynaMO: Abiraterone Acetate, Prednisone, and Apalutamide With or Without Ipilimumab or Cabazitaxel and Carboplatin in Treating Patients With Metastatic Castration-Resistant Prostate Cancer (clinicaltrials.gov)
    P2, N=196, Active, not recruiting, M.D. Anderson Cancer Center | Trial completion date: May 2025 --> Mar 2026 | Trial primary completion date: May 2025 --> Mar 2026
    Trial completion date • Trial primary completion date • Metastases
    |
    AR (Androgen receptor)
    |
    Yervoy (ipilimumab) • carboplatin • abiraterone acetate • prednisone • cabazitaxel • Erleada (apalutamide)
    7ms
    Long-term outcomes of a randomized, open-label, phase II study comparing cabazitaxel versus paclitaxel as neoadjuvant treatment in patients with triple-negative or luminal B/HER2-negative breast cancer (GENEVIEVE). (PubMed, ESMO Open)
    The significant differences in pCR rates observed in both treatment arms did not significantly impact long-term outcomes for patients treated with cabazitaxel versus paclitaxel in the GENEVIEVE trial.
    P2 data • Journal
    |
    HER-2 (Human epidermal growth factor receptor 2) • PGR (Progesterone receptor)
    |
    HER-2 negative • ER positive + PGR positive • PGR positive
    |
    paclitaxel • cabazitaxel
    7ms
    Activity of Lutetium-177 Prostate-specific Membrane Antigen and Determinants of Outcomes in Patients with Metastatic Castration-resistant Prostate Cancer Previously Treated with Cabazitaxel: The PACAP Study. (PubMed, Eur Urol Oncol)
    Lu-PSMA demonstrated a substantial PSA decline but limited rPFS after cabazitaxel in a real-life setting. Adverse baseline characteristics, baseline positron-emission tomography parameters, and quality of PSA response may help identify patients less likely to benefit from Lu-PSMA.
    Journal • Metastases
    |
    ADCYAP1 (Adenylate Cyclase Activating Polypeptide 1)
    |
    docetaxel • cabazitaxel
    7ms
    Real World Evidence Study on Metastatic Prostate Cancer in the Pirkanmaa Hospital District in Finland (clinicaltrials.gov)
    P=N/A, N=1, Completed, Pfizer | Trial completion date: Jun 2023 --> Apr 2024 | Trial primary completion date: Jun 2023 --> Apr 2024
    Trial completion date • Trial primary completion date • HEOR • Real-world evidence • Real-world • Metastases
    |
    docetaxel • Xtandi (enzalutamide capsule) • abiraterone acetate • cabazitaxel • Erleada (apalutamide) • triptorelin • goserelin acetate • Firmagon (degarelix) • Xofigo (radium Ra-223 dichloride) • leuprolide acetate for depot suspension
    7ms
    Kinesin Facilitates Phenotypic Targeting of Therapeutic Resistance in Advanced Prostate Cancer. (PubMed, Mol Cancer Res)
    Combinational targeting of kinesins (ispinesib) with cabazitaxel was more effective than single monotherapies in inducing cell death in resistant prostate tumors. Implications: Our findings are of translational significance in identifying kinesin as a novel target of cross-resistance, towards enhancing therapeutic vulnerability and improved clinical outcomes in patients with advanced prostate cancer.
    Journal • Metastases
    |
    CDH1 (Cadherin 1) • SLCO1B3 (Solute carrier organic anion transporter family member 1B3) • VIM (Vimentin) • KIFC1 (Kinesin Family Member C1)
    |
    CDH1 expression • VIM expression • CDH1 overexpression
    |
    cabazitaxel • ispinesib (SB-715992)
    7ms
    A Randomised Trial of Cabazitaxel, Docetaxel, Mitoxantrone or Satraplatin (CDMS) Plus Surgery for Prostate Cancer Patients Without Metastasis (clinicaltrials.gov)
    P1, N=50, Recruiting, Shanghai Jiao Tong University School of Medicine | Trial completion date: Dec 2025 --> Dec 2027 | Trial primary completion date: Dec 2024 --> Dec 2026
    Trial completion date • Trial primary completion date • Surgery
    |
    docetaxel • mitoxantrone • cabazitaxel • Orplatna (satraplatin)
    8ms
    Substudy 01A: Safety and Efficacy of MK-5684-based Treatment Combinations or MK-5684 Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A) (clinicaltrials.gov)
    P1/2, N=220, Not yet recruiting, Merck Sharp & Dohme LLC
    New P1/2 trial • Metastases
    |
    Lynparza (olaparib) • docetaxel • cabazitaxel • opevesostat (MK-5684)
    8ms
    Cabazitaxel With Radiation and Hormone Therapy for Prostate Cancer (clinicaltrials.gov)
    P1, N=20, Completed, Sidney Kimmel Cancer Center at Thomas Jefferson University | Active, not recruiting --> Completed
    Trial completion • Metastases
    |
    bicalutamide • cabazitaxel
    8ms
    CABPOSTAAT: Docetaxel Versus Cabazitaxel Post Abiraterone or Enzalutamide (clinicaltrials.gov)
    P2, N=214, Active, not recruiting, Centre hospitalier de l'Université de Montréal (CHUM) | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    docetaxel • Xtandi (enzalutamide capsule) • abiraterone acetate • prednisone • cabazitaxel
    8ms
    Association between the apoptotic effect of Cabazitaxel and its pro-oxidant efficacy on the redox adaptation mechanisms in prostate cancer cells with different resistance phenotypes. (PubMed, Cancer Biol Ther)
    Moreover, the cytotoxic and apoptotic effects of Cab were less on RWPE-1 cells compared to LNCaP but were closer to those on the more aggressive LNCaP-HPR and C4-2 cells, except for the changing pro-oxidant effect of Cab. Consequently, this study indicates the variable pro-oxidant effects of Cab on redox-sensitive proteins, which could be a target for improving Cab's apoptotic effect more in aggressive PC cells.
    Journal
    |
    HIF1A (Hypoxia inducible factor 1, alpha subunit)
    |
    cabazitaxel
    8ms
    FOcal Radiation for Oligometastatic Castration-rEsistant Prostate Cancer (FORCE) (clinicaltrials.gov)
    P2, N=13, Completed, University of Michigan Rogel Cancer Center | Active, not recruiting --> Completed | Trial completion date: Mar 2024 --> Jul 2023
    Trial completion • Trial completion date • Metastases
    |
    docetaxel • Xtandi (enzalutamide capsule) • abiraterone acetate • cabazitaxel
    9ms
    XmAb®20717 (Vudalimab) Alone or in Combination With Chemotherapy or Targeted Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer (clinicaltrials.gov)
    P2, N=85, Recruiting, Xencor, Inc. | Trial completion date: Jun 2024 --> Sep 2025 | Trial primary completion date: Jun 2023 --> Mar 2025
    Trial completion date • Trial primary completion date • Combination therapy • Tumor mutational burden • Metastases
    |
    TMB (Tumor Mutational Burden) • MSI (Microsatellite instability) • HRD (Homologous Recombination Deficiency)
    |
    TMB-H • MSI-H/dMMR
    |
    Lynparza (olaparib) • carboplatin • docetaxel • cabazitaxel • vudalimab (XmAb717)
    9ms
    Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial (clinicaltrials.gov)
    P1, N=2, Terminated, OHSU Knight Cancer Institute | Active, not recruiting --> Terminated; Low accrual
    Trial termination
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • Avastin (bevacizumab) • Venclexta (venetoclax) • Lynparza (olaparib) • Mekinist (trametinib) • erlotinib • Gilotrif (afatinib) • Yervoy (ipilimumab) • Ibrance (palbociclib) • dasatinib • Zelboraf (vemurafenib) • Tafinlar (dabrafenib) • carboplatin • Imfinzi (durvalumab) • sorafenib • Rozlytrek (entrectinib) • imatinib • sunitinib • everolimus • Nerlynx (neratinib) • Iclusig (ponatinib) • Kadcyla (ado-trastuzumab emtansine) • Cotellic (cobimetinib) • Lorbrena (lorlatinib) • Lenvima (lenvatinib) • bortezomib • doxorubicin hydrochloride • capecitabine • Verzenio (abemaciclib) • Xtandi (enzalutamide capsule) • Cabometyx (cabozantinib tablet) • albumin-bound paclitaxel • Stivarga (regorafenib) • abiraterone acetate • oxaliplatin • Aliqopa (copanlisib) • Vizimpro (dacomitinib) • Zydelig (idelalisib) • daunorubicin • Zolinza (vorinostat) • Idhifa (enasidenib) • Farydak (panobinostat) • Erivedge (vismodegib) • Nubeqa (darolutamide) • bicalutamide • leucovorin calcium • cabazitaxel • Vesanoid (tretinoin) • fluorouracil topical